Evolus, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US30052C1071
USD
6.97
0.23 (3.41%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Kiniksa Pharmaceuticals Ltd.
PetIQ, Inc.
Tarsus Pharmaceuticals, Inc.
Repare Therapeutics, Inc.
Travere Therapeutics, Inc.
Phathom Pharmaceuticals, Inc.
Viridian Therapeutics, Inc.
Evolus, Inc.
Rapt Therapeutics, Inc.
GH Research Plc
Genelux Corp.

Why is Evolus, Inc. ?

1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Operating profit has grown by an annual rate 7.75% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -7.67
2
Flat results in Mar 26
  • OPERATING CASH FLOW(Y) Lowest at USD -36.58 MM
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -27.55%, its profits have fallen by -23.1%
4
Underperformed the market in the last 1 year
  • Even though the market (S&P 500) has generated returns of 20.78% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -27.55% returns
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Evolus, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Evolus, Inc.
-27.55%
-0.56
69.65%
S&P 500
20.78%
1.56
13.28%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
39.36%
EBIT Growth (5y)
7.75%
EBIT to Interest (avg)
-7.67
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-8.46
Sales to Capital Employed (avg)
2.09
Tax Ratio
1.24%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-11.29
EV to EBIT
-9.46
EV to EBITDA
-12.33
EV to Capital Employed
4.96
EV to Sales
1.20
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-52.45%
ROE (Latest)
Negative BV
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
NET PROFIT(HY)

Higher at USD -11.7 MM

-4What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at USD -36.58 MM

Here's what is working for Evolus, Inc.

Net Profit
Higher at USD -11.7 MM
than preceding 12 month period ended Mar 2026
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Depreciation
Highest at USD 2.69 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Evolus, Inc.

Operating Cash Flow
Lowest at USD -36.58 MM
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)